- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Scott Lassman: Drug Pricing Legislation
Scott Lassman, JD, partner in Goodwin's Technology and Life Sciences Group, describes trends in state legislation on drug pricing and industry reaction to such laws.
Transcript:
Despite challenges from industry groups, a number of states have recently enacted drug pricing regulation. Do you expect to see more states passing such laws?
I think I just read that there were 2 more states that had either proposed or enacted similar legislation to what Maryland passed. This is an outgrowth of the whole concern about drug pricing, so I think it’s something that’s going to continue.
The pharmaceutical companies and the associations I think are going to continue to fight against those, and I think they’re going to do it for a number of reasons. One, a lot of the laws are somewhat vague and make it difficult to determine whether someone is violating the law or not.
The other big issue is, when you’ve got different requirements in different states it makes it very difficult for companies to price their products. I think there’s going to be a big push to try and get some sort of national standard.
We saw this many years ago with clinical trial disclosure requirements. A number of states started enacting laws requiring companies to disclose clinical trial information; I think Maine was the first one. Again, industry was very concerned about having multiple, disparate requirements from state to state, so they pushed for a national requirement, and that was enacted back in 2007. This is one of those issues that I think companies will want to have any national legislation, but I think they are going to fight against having different requirements in different states.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
